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Abstract
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Metastasis, drug resistance and recurrence in cancer are regulated by the tumor microenvironment.
This review describes recent advances in understanding how cancer cells respond to extracellular
environmental cues via integrins, how to build engineered microenvironments to study these
interactions in vitro and how nanomaterials can be used to detect and target tumor
microenvironments.
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Introduction

Author Manuscript

Cells are responsive to the biochemical and biomechanical features of the extracellular
matrix (ECM). These responses (e.g., proliferation, apoptosis, migration and differentiation)
are crucial for health at all levels. Cancer cells share many of the responsive properties of
healthy cells. However, they differ from normal cells because their responses to ECM are
often dysregulated and they exhibit drug resistance and the ability to form recurrent tumors.
Understanding how cancer cells respond to ECM cues provides access to new avenues for
treatment complementary to our current arsenal of cancer therapies.
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In this short review, we will discuss recent advances in understanding how cancer cells
respond to their environment via integrins with a particular focus on the mechanobiological
properties of the ECM (Figure 1). We will also present recent findings on how the size-scale
provided by nanomaterials can be used to change these environments for therapeutic
purposes.

Integrins and cancer cells

Author Manuscript

Integrins are transmembrane glycoproteins that mediate interactions between cells and the
ECM and link the ECM to the cytoskeleton [1]. Integrins sense the ECM and relay this
information to downstream signaling pathways to control cell movement, growth and gene
expression [1]. This function is of considerable importance in cancer because the ability of
integrins to interact with the ECM in the tumor microenvironment and sense biochemical
and biomechanical perturbations in this ECM is a key determinant of tumor growth and
progression to metastatic disease [2]. Therefore the ECM is a key determinant of tumor
growth and progression to metastatic disease [2]. Indeed, the literature is full of studies that
describe the contribution of integrins to various aspects of cancer cell behavior. Some of the
more interesting and provocative work in this area that has emerged recently relates to the
importance of ECM–integrin interactions in the function of cancer stem cells (CSCs) and
metastasis and the ability of integrins to transduce mechanical forces generated by the ECM
(see below). Although these roles are not mutually exclusive, they will be discussed
separately here.
CSCs

Author Manuscript

Most tumors harbor a population of cells with characteristics of stem cells including the
ability to self-renew and populate new tumors [3,4]. This population, often referred to as
CSCs or tumor-initiating cells, is resistant to most standard chemotherapies and thought to
contribute to tumor dormancy and recurrence. CSCs differ from non-CSCs in their
expression of specific integrins and these integrins are frequently used as cell surface
markers to enrich for CSC populations [5]. Notable examples include the α6 integrins (α6β1
and α6β4) and the αvβ3 integrin [2]. Moreover, it has become increasingly apparent that
specific integrins contribute to sustaining stem cell properties by transducing cues from the
ECM present in the CSC niche [6–8]. CSC niches are complex microenvironments primarily
comprising CSCs, non-CSCs (cancer-associated fibroblasts, inflammatory cells) and ECM,
as well as secreted factors (cytokines, growth factors) [8]. The CSC niche can be considered
as a specialized form of the tumor microenvironment that functions to maintain stem cell
properties, including self-renewal [8].

Author Manuscript

The biochemical and biomechanical properties of the ECM in the CSC niche exert profound
effects on CSC function. Tenascins, periostin and laminins are among the ECM proteins that
have been implicated in regulating CSC function [2,8]. The laminins are of particular
interest in this regard because they exemplify the specificity of ECM cues in controlling
CSCs. Among this large family of ECM proteins, one laminin (LM511) appears to be crucial
for maintaining stemness. Breast CSCs, for example, deposit a LM511 matrix that sustains
stem cell properties (self-renewal and tumor initiation; Figure 2) [7]. Surface-bound LM511
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can be used as a marker to enrich for CSCs and, potentially, to detect CSCs in tumor
sections [7]. Interestingly, LM511 is recognized by a specific, cytoplasmic domain splice
variant of the α6β1 integrin (α6Bβ1) and this interaction activates a crucial signaling
pathway involving the Hippo transducer TAZ which is necessary for the function of breast
CSCs [7]. These findings reveal the exquisite specificity of ECM–integrin interactions in
regulating stemness because only one of the two splice variants of the α6β1 integrin has the
ability to recognize a specific laminin, which is crucial for stemness. This specificity
provides opportunities for therapeutic targeting of CSCs, which has become the holy grail of
cancer therapy. Future work should focus on understanding the unique biochemical and
biomechanical properties of LM511 that confer stemness compared to other laminins and
the recognition of this laminin by α6Bβ1.

Author Manuscript

The ability of integrins to promote stemness can occur independently of binding to ECM.
This scenario is exemplified best by studies on the αvβ3 integrin, which contributes to the
function of mammary and breast CSCs by enhancing the expression of Slug, a transcription
factor that is a master regulator of stemness [9]. Antagonists that compete for αvβ3 ligand
binding have no effect on mitigating stem cell properties [10]. The ability of αvβ3 to
promote stemness in the absence of ECM engagement provides autonomy and selfsufficiency to CSCs. Nevertheless, it is also evident that CSCs are dependent on cues from
secreted factors, as well as other ECM–integrin interactions as described above. Clearly, a
systems approach is needed to integrate the complex array of signals from the CSC niche
and those intrinsic to CSCs that impact stemness.
Metastasis

Author Manuscript

The concept of the premetastatic niche provides an ideal example of the importance of
external cues in cancer progression. This niche is a specialized microenvironment,
comprising ECM (especially tenascin-C and periostin) and other molecules, which forms at
potential metastatic sites in response to cues from the primary tumor [11,12]. Understanding
how the primary tumor communicates the formation of the niche before the arrival of tumor
cells is a fascinating problem. Recent studies implicate a key role for exosomes, which are
small membrane vesicles that contain DNA, RNA, proteins and lipids [13]. Exosomes
formed from primary tumor cells have the potential to home in distant organs and facilitate
formation of the premetastatic niche [14].
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An exciting advance in this field is the discovery that exosome integrins determine the organ
specificity of the premetastatic niche and subsequent metastasis [15]. Exosomes destined for
the lung, for example, express the α6β4 integrin, which is a laminin receptor [16], and are
taken up by laminin-rich cells in the lung [14]. The fusion of these exosomes and their
associated content with resident cells contributes to the formation of the premetastatic niche.
These data substantiate previous work implicating the α6β4 integrin in metastasis and they
strengthen its potential as a therapeutic target [17]. They also raise several provocative and
timely questions. Given that laminin is present in all organs, what is distinct about the
laminin in the lung (isoform specificity, location, mechanical properties) that enables it to
function as a cue for α6β4-containing exosomes? Another intriguing consideration is how
the formation of specific exosomes is regulated in the primary tumor. Given that exosomes
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are formed by the fusion of multivesicular endosomes with the plasma membrane [7], what
are the signals that trigger the formation of α6β4-containing exosomes for example? Is their
formation linked to integrin endocytosis and recycling [18]? It is worth noting in this context
that hypoxia selects for cells with metastatic potential [19], increases exosome formation
and stimulates trafficking of the α6β4 integrin [20].

Mechanobiology and cancer

Author Manuscript

Studying the ability of a cell to sense and respond to mechanical cues has emerged as a field
in itself over the past 20 years, and the importance of the mechanical environment on cell
and/or tissue behavior is now appreciated by engineers and biologists alike. Growing
evidence is proving that the ECM plays a crucial part in regulating tumor growth and
metastasis [21], and stiffness is one of the ECM features responsible for tumor evolution.
Tumor ECM is notoriously stiff (up to tens of kPa) relative to healthy tissue (hundreds of Pa)
[22]; a difference that is associated with extensive changes in the metastatic potential of cells
within the tumor [23]. The cellular response to mechanical influences from the ECM is
mediated by integrins that not only provide tissue-specific cell attachment to ECM proteins
but also activate biochemical signaling networks in response to static and dynamic
mechanical forces [24]. A salient example of this phenomenon that relates to the previous
discussion of integrins is that simply increasing ECM stiffness is sufficient to induce the
malignant transformation of normal mammary epithelial cells, a process that is mediated by
α6β4 integrin signaling [25,26].

Author Manuscript

Tumor stiffening is derived from an increase in fibrillar type 1 collagen, deposited by
cancer-associated fibroblasts (CAFs) [27] and adipogenic stem cells (ASCs) [28]. During
tumor growth, collagens become increasingly fibrillar and organize into tight bundles. Some
propose that collagen reorganization [29] and tumor (and stroma) stiffness [30] could be
used as a prognostic tool for metastatic risk or progression in patients via imaging or
minimally invasive biopsy.
Metastasis

Author Manuscript

After cells have invaded the primary tumor stroma and intravasated local vasculature, those
few cells that are able to survive the journey will eventually encounter secondary tissues that
are biochemically and mechanically diverse. The mechanosensing of cells and these
destination tissues is a newer, but active, area of research. Researchers are using a variety of
techniques to quantify the rigidity of these tissue sites. Examples include brain tissue (1–2
kPa in Young’s modulus) [31], lung (2–8 kPa) [32], trabecular and cortical bone being (~10
GPa) and bone marrow (0.3–24.7 kPa) [33]. Engineers are using these analyses as
inspiration to create in vitro model systems that capture the mechanical features of these
diverse tissues [34], with the goal of elucidating the mechanisms of this mechanosensing,
and eventually developing drugs to abrogate it.
Preliminary evidence points to tissue mechanics, alongside ECM binding [35], as one aspect
that controls tissue-specific metastatic spread. Kostic et al. showed that cells that typically
spread to certain tissues (e.g., brain, bone) also migrated faster and grew faster on substrates
that were mechanically close to those destination tissues [36]. In a comparative study,
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McGrail et al. demonstrated that ovarian cancer cell lines proliferated more and migrated
faster on softer gels compared with breast cancer cells [37]. The authors suggest that this
difference in migration rates mirrors the observation that ovarian cancer generally
metastasizes to softer tissues than breast cancer. More-complex systems have emerged with
the ability to combine mechanical cues with other facets of the tumor microenvironment,
including vascularization [38], or tissue-specific features, typically from decellularized
tissue sources [39]. What is needed to catapult these phenomenological studies into
therapeutic targets is to identify the signaling networks downstream of integrin binding
responsible for translating the mechanical signaling to metastasis. One recent example is the
Rho/ROCK pathway – implicated in stiffness-mediated metastasis [27]. Another is the
emerging role of YAP/TAZ as mechanotransducting nodes in the Hippo pathway [40].
Coupling these in vitro systems with phosphoproteomic and genomic sequencing could
eventually connect the important studies in carefully controlled microenvironments to
interrogation of integrin-mediated signaling for in vivo and clinical utility to stop metastasis
from stiff tumors, or halt their ability to reach secondary sites with a certain mechanical
profile.
Drug resistance

Author Manuscript

Drug resistance in cells and patients is a well known problem in cancer. During drug
development, potential drug resistance can be missed, because chemotherapeutics and small
molecule drugs are screened in ‘plastic’ microenvironments before preclinical and clinical
trials, and these plastic environments do not resemble the natural environment of a cell or
tumor. There is currently emphasis on the intracellular and genetic mechanisms of drug
resistance. However, to make a paradigm shift in this field, many are now beginning to
account for the mechanical environment of the cell as it responds to drugs. Given that
mechanics regulate metastasis and tumor growth, similar intracellular proteomic networks
could be rewired during tumor stiffening that hinder the efficacy of cancer drugs.

Author Manuscript

The ideal in vitro drug-testing platform to parse the role of mechanics in drug response
would present matrix cues (such as stiffness and cell-binding peptides) relevant to what
cancer cells experience in vivo in a 3D, high-throughput manner. A recent example is a 4D
lung model, in which circulating tumor cells were equally resistant to cisplatin in the model
system as they were in vivo, results that were not captured on 2D surfaces [41]. Similarly,
combining ovarian cancer cells with fibroblasts in a representative ECM system
recapitulated in vivo drug response better than monoculture models [42]. These types of
organotypic representations of tissue for drug screening are likely to become increasingly
popular with the advent of patient-derived cultures [43]. These patient-derived systems are
relatively low-throughput, and a high-throughput aspect is crucial to making it accessible to
pharmaceutical companies. Synthetic hydrogels have been adapted into multi-well plates to
overcome this throughput issue, the first of which uses polyacrylamide (PAA) gels to show
that stiffness regulated cancer cell growth in the presence of a few candidate drugs [44].
Other 2D systems have more recently emerged, including other mechanisms to prepare PAA
gels [45], and those based on polyethylene glycol (PEG) [46]. These examples include not
only response to common chemotherapeutics (e.g., paclitaxel) [45] but also how signaling
networks perturbed during ECM stiffening provide resistance to receptor tyrosine kinase
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inhibitors (e.g., sorafenib, lapatinib) [46,47]. Ideally, future work will translate these initial
results into better-informed drug treatment and monitoring, with delivery systems
incorporating tissue-specific targeting facilitated by nanomaterials.

Nanomaterials for regulating cancer cell behaviors
Nanomaterials are materials with sizes between 1 and 100 nm, corresponding to a size-scale
ranging from that of small proteins to large cellular organelles. They can be engineered in a
particular way to represent some of the key features of ECM, such as hydrophobicity, charge
and topology, providing unique tools for fundamental studies of cell–environment
interactions and therapeutic applications [48].
Chemical environment and cell behavior
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We have discussed above how the specific chemical signals provided by integrins and the
mechanical environment of the ECM regulate cancer cell behavior. The physicochemical
environment of the ECM likewise plays a significant part, as demonstrated by the role of cell
glycosylation in cancer progression. This interplay has been studied using chemically
modified surfaces of substrates, however control of chemical functionality and topology
remain a challenge. Nanomaterials provide a tool for controlling both aspects by ‘painting’
on pre-functionalized nanomaterials. As an example, Cui et al. have recently used polymerfunctionalized nanoparticles to demonstrate that hydrophobic nanomaterials inhibit HeLa
cell proliferation [49]. This study presented one axis of the physicochemical environment;
however the ECM presents a range of stimuli including charge and topology as well as
hydrophobicity. Tang et al. have used small (2 nm core) gold nanoparticles functionalized
with a wide range of surface ligands to probe cell proliferation with four different cancer cell
lines (Figure 3) [50]. These studies showed that cationic functionality enhanced cell
proliferation. More interesting, however, was the fact that specific chemical moieties (e.g.,
aromatic groups) had differential responses between the cell lines studied. This outcome
suggests that modulation of the local chemical environment of cells provides a potential
strategy for selectively regulating cancer cell behavior, as discussed below.
The above studies used 2D cell culture techniques, which are clearly an abstraction of the
3D nature of tumors. Grzincic and Murphy studied the effects of gold nanorods in 3D
collagen matrices, discovering that these nanomaterials accelerated cell migration of breast
tumor cells, enabling a rounded ‘amoeboid-like’ phenotype [51] not normally observed in
2D systems.
Nanomaterials as environmental therapeutics

Author Manuscript

The broadest application of nanomaterials in medicine has been as delivery vehicles for
therapeutic small molecules and biomacromolecules [52]. They have also been used as
intracellular self-therapeutics for regulating cellular processes. Nanomaterials have recently
emerged that mimic and/or alter the cellular environment, providing new strategies for
nanotherapeutics. One particularly interesting application was the use of nanoparticles
coated with ECM from tumor-associated fibroblasts to capture cancer cells, thereby
preventing peritoneal metastasis [53]. Another example of a nanotherapeutic approach lies in
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altering stemness of CSCs. The ability of CSCs to self-renew and differentiate into multilineage provides a challenging yet potentially high-payoff target for therapeutic strategies.
Just as environmental effects can be used to regulate normal stem cell differentiation, CSCs
can be induced to differentiate through environmental cues. For instance, gadolinium
fullerene Gd@C82(OH)22 was reported to block epithelial-to-mesenchymal transition of
triple-negative breast cancer cells [54], without any toxicity to normal mammary epithelial
cells. Gd@C82(OH)22 successfully suppressed breast tumor growth in vivo. Hydrophobicity
appears to be an important consideration in CSC interactions, because graphene-oxide (GO)
was also reported to work as a therapeutic strategy against CSCs via de-stemming, as
demonstrated through a lack of spheroid formation [55].

Concluding remarks
Author Manuscript

The biochemical and biomechanical microenvironment of tumors is a key factor in
metastasis and drug resistance. Understanding the part these factors play in cancer
progression provides new strategies for therapeutics. We present here how biomolecules
(e.g., integrins) and nanomaterials alter cancer cell behavior through chemical means, and
how mechanobiology is a key factor in understanding and treating cancer progression. Taken
together, this work shows that targeted presentation of external cues has the potential to
complement current intracellular cancer therapy strategies.
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•

Biomolecules including integrins are key factors in cancer progression

•

Nanomaterials provide tools for regulating the chemical environment of
cells

•

Mechanobiology is an emerging determinant in designing cancer
therapies
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Figure 1.

Representative examples of how external cues dictate cell behavior.
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Surface-bound LM511 identifies breast cancer cells with stem cell properties. (a) Sections of
human breast tumors were stained with an antibody that recognizes the a5 subunit of LM511
using either immunohistochemistry (top) or immunofluorescence (bottom). Note the small
number of cells with intense LMa5 staining on their surfaces (arrows). (b) Three primary
human breast tumors (T1, T2 and T3) were dissociated and sorted by FACS using a LMa5
Ab. Cells with low surface-bound LMa5 (P1, P3 and P4) were compared with cells with
high surface-bound LMa5 (P2, P4 and P6) for their ability to form mammospheres. (c) Note
that cells with high surface-bound LMa5 had the ability to form mammospheres. Adapted,
with permission, from [7].
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Figure 3.

Relationship between cell viabilities of four different cancer cells and different AuNP
coatings for 2 nm core AuNPs immobilized on polystyrene surfaces. (a) A heat map of cell
viability on different AuNP coatings. (b) Structures of ligands on the AuNPs. Adapted, with
permission, from [50].
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